Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)‘s stock had its “outperform” rating reaffirmed by stock analysts at Leerink Swann in a report released on Tuesday. They currently have a $94.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $85.00. Leerink Swann’s price objective would suggest a potential upside of 22.75% from the stock’s current price.

Several other research analysts also recently commented on RARE. Jefferies Group reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Sunday, July 17th. Cowen and Company reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, August 9th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $101.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, August 9th. Wedbush reaffirmed an “outperform” rating and issued a $92.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Monday. Finally, JMP Securities reaffirmed a “buy” rating and issued a $84.00 price objective (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 8th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Ultragenyx Pharmaceutical currently has an average rating of “Buy” and an average price target of $97.89.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up 1.574% on Tuesday, reaching $77.785. 161,212 shares of the company’s stock were exchanged. Ultragenyx Pharmaceutical has a 52-week low of $46.52 and a 52-week high of $117.12. The stock’s market cap is $3.07 billion. The company’s 50 day moving average price is $67.24 and its 200-day moving average price is $62.97.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ultragenyx-pharmaceutical-inc-rare-earns-outperform-rating-from-leerink-swann.html

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.02. During the same period in the previous year, the business earned ($0.83) earnings per share. Equities analysts forecast that Ultragenyx Pharmaceutical will post ($5.93) EPS for the current fiscal year.

In related news, insider Sunil Agarwal sold 649 shares of the stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total value of $34,189.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $67.61, for a total value of $1,352,200.00. Following the completion of the transaction, the chief executive officer now owns 493,244 shares in the company, valued at $33,348,226.84. The disclosure for this sale can be found here. Company insiders own 10.10% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth about $100,000. DIAM Co. Ltd. bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at $177,000. Springbok Capital Management LLC bought a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at $189,000. BlackRock Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 58.5% in the second quarter. BlackRock Inc. now owns 3,973 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,467 shares during the period. Finally, Creative Planning boosted its position in shares of Ultragenyx Pharmaceutical by 16,700.0% in the second quarter. Creative Planning now owns 4,200 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 4,175 shares during the period. Institutional investors own 93.06% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.